Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $522.50 MXN
Change Today 0.00 / 0.00%
Volume 0.0
PFE* On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
As of 4:09 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE*) Snapshot

Open
$525.55
Previous Close
$522.50
Day High
$525.55
Day Low
$521.01
52 Week High
04/24/15 - $544.66
52 Week Low
08/12/14 - $369.18
Market Cap
3.2T
Average Volume 10 Days
22.0K
EPS TTM
--
Shares Outstanding
6.1B
EX-Date
05/6/15
P/E TM
--
Dividend
$1.12
Dividend Yield
2.98%
Current Stock Chart for PFIZER INC (PFE*)

pfizer inc (PFE*) Details

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women’s/men’s health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has collaboration with BIND Therapeutics, Inc. to develop and commercialize multiple Accurins. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

78,300 Employees
Last Reported Date: 02/27/15
Founded in 1849

pfizer inc (PFE*) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.3M
President of Worldwide Research & Development
Total Annual Compensation: $1.2M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $1.2M
Group President of Global Established Pharma ...
Total Annual Compensation: $1.0M
Compensation as of Fiscal Year 2014.

pfizer inc (PFE*) Key Developments

23andMe, Inc. Launches Lupus Research Study in Collaboration with Pfizer Inc

23andMe, Inc. announced the launch of the Lupus Research Study in collaboration with Pfizer Inc. The companies aim to enroll 5,000 individuals with systemic lupus erythematosus, more commonly known as lupus, into the study to help better understand the genetics of lupus. The effort is also in collaboration with the Lupus Research Institute, and in concert with Lupus Awareness Month in May.

Pfizer Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 through May-05-2015

Pfizer Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 through May-05-2015. Venue: Time Warner Center, New York, United States. Presentation Date & Speakers: May-04-2015, Sandra Engle, Senior Principal Scientist. May-05-2015, Cyndi Green, Senior Director, Worldwide Business Development.

Pfizer To Acquire Swedish Orphan Biovitrum

As per reports Swedish Orphan Biovitrum AB (OM:SOBI) had received an offer to be acquired earlier this week. It has been revealed that the preliminary offer had come from Pfizer Inc. (NYSE:PFE). The price that Pfizer has offered could not be learned. Spokesmen for both Sobi and Pfizer declined to comment. Pfizer Chief Executive Officer Ian Read said on Tuesday during an earnings call that he was open to deals and was "agnostic" about the size of acquisitions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE*:MM $522.50 MXN 0.00

PFE* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $103.07 USD +0.08
Merck & Co Inc $60.52 USD +0.03
Nestle SA SFr.71.40 CHF -0.85
Roche Holding AG SFr.262.60 CHF -4.50
Procter & Gamble Co/The $79.78 USD -0.29
View Industry Companies
 

Industry Analysis

PFE*

Industry Average

Valuation PFE* Industry Range
Price/Earnings 23.8x
Price/Sales 4.3x
Price/Book 3.0x
Price/Cash Flow 16.2x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.